Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
14
11
2018
accepted:
12
03
2019
revised:
06
03
2019
pubmed:
13
4
2019
medline:
7
7
2020
entrez:
13
4
2019
Statut:
ppublish
Résumé
Standard clinical parameters fail to accurately differentiate indolent from aggressive prostate cancer. Our previous studies showed that immunohistochemical testing for Ki-67 improved prediction of prostate cancer death in a previous cohort of conservatively treated clinically localized prostate cancer. However there is a need for validation of usage with whole biopsy sections rather than tissue micro-arrays for use in routine diagnostics. Prostate cancer biopsy cases were identified in the UK, between 1990 and 2003, treated conservatively. Tumor extent and prostate-specific antigen (PSA) serum measurements were available. Biopsy cases were centrally reviewed by three uropathologists and Gleason conformed to contemporary ISUP 2014 criteria. Follow-up was through cancer registries up until 2012. Deaths were divided into those from prostate cancer and those from other causes. The percentage of Ki-67 in tumor cells was evaluated by immunohistochemistry on whole biopsy sections and was available for 756 patients. This percentage was used in analysis of cancer specific survival using a Cox proportional hazards model. In univariate analysis, the interquartile hazard ratio (HR) (95% confidence intervals) for continuous Ki-67 was 1.68 (1.49, 1.89), χ
Identifiants
pubmed: 30976102
doi: 10.1038/s41379-019-0268-y
pii: S0893-3952(22)01017-1
pmc: PMC8647491
mid: NIHMS1759524
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
MKI67 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1303-1309Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009629
Pays : United States
Références
Biomed Res Int. 2014;2014:341324
pubmed: 25243131
N Engl J Med. 2012 Jul 19;367(3):203-13
pubmed: 22808955
J Clin Oncol. 2004 Jun 1;22(11):2133-40
pubmed: 15169799
J Urol. 1997 Jan;157(1):219-22
pubmed: 8976256
Urol Oncol. 2017 Aug;35(8):499-506
pubmed: 28648414
Mayo Clin Proc. 2014 Mar;89(3):308-18
pubmed: 24486077
Am J Surg Pathol. 2011 Jun;35(6):853-60
pubmed: 21566513
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4118-24
pubmed: 15217948
Eur Urol. 2018 Sep;74(3):357-368
pubmed: 29937198
Urol Oncol. 2018 Apr;36(4):161.e7-161.e17
pubmed: 29174711
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
J Clin Oncol. 2009 Jul 1;27(19):3177-84
pubmed: 19470936
Br J Cancer. 2009 Mar 24;100(6):888-93
pubmed: 19293807
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
World J Urol. 2018 Sep;36(9):1495-1500
pubmed: 29679140
Lancet Oncol. 2011 Mar;12(3):245-55
pubmed: 21310658
J Urol. 2010 Feb;183(2):433-40
pubmed: 20006878
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
PLoS One. 2017 Nov 15;12(11):e0186852
pubmed: 29141018
Acta Oncol. 2018 Jan;57(1):102-106
pubmed: 29202620
Virchows Arch. 2017 Oct;471(4):501-508
pubmed: 28497316
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Br J Cancer. 2013 Feb 5;108(2):271-7
pubmed: 23329234
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70
pubmed: 27136741
Br J Cancer. 2016 Jul 12;115(2):236-42
pubmed: 27336609